Who Attends
The program is designed for all size pharma/biotech companies, academia and investors seeking to enable a patient’s immune system to eradicate cancer.
.png)
Biopharma Responsible for
- Cancer Immunotherapy
- Immuno-Oncology
- R&D Innovation & Strategy
- Clinical R&D
- Business Development
- Preclinical and Translational Research
- Biomarkers and Companion Dx
- Early Stage Collaborations
- Clinical Operations
- Strategic Partnerships
- External R&D
- Licensing & Commercial Strategy
Solution Providers
- Diagnostic Testing
- Biomarkers and Companion Dx
- Assay Development
- Next Gen Sequencing
- mRNA / DNA Nucleic Acid Processing
- RNA Sequencing
- Cell Analysis/Manufacturing Platforms
- Liquid Biopsies
- Cancer Genetics
- Immune Monitoring
- Imaging Services
- Flow Cytometry
- Data Analysis/Analytics
- Laboratory Services
- Artificial Intelligence
- CROs/Clinical Trial Design
Investment Community Including
- Investment Firms
- Banks/Financial Institutions
- Venture Capital
- Private Equity
- Foundation Capital
- Analysts
Academia & Research Organization Focusing on
- Immuno-Oncology / Cancer Immunotherapy
- Oncology
- Immunology
- Cancer Vaccines
- Adoptive T-Cell Therapy
- Preclinical & Clinical R&D
.png)
.png)
.png)
"IO360° was one of the best immuno-oncology meetings I’ve been to. Kudos! Great speakers and great dialogue!"
- Jim Mansfield, PerkinElmer
.jpg)
IO360˚ is a strategic-level conference where Pharma and Biotech present along with academia and investors and hold partnering meetings so as a community we can drive faster advancements to eradicate cancer.
Immuno-Oncology 360° delivers three key benifits:
1. Access to KOLs driving the science
2. Partnership opportunities with all stakeholders in Immuno-Oncology
3. Presentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology
2024 Sponsors
